02511 HIGHTIDE-B
- 5.840
- -0.240-3.95%
HIGHTIDE-B News
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
君聖泰醫藥-B：2023年報
Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) once rose more than 42% and previously announced the completion of the phase IIb clinical trial of HTD1801 to enroll patients
Junshengtai Pharmaceutical-B (02511) once rose by more than 42%. As of press release, it rose 23.49% to HK$5.31, with a turnover of HK$12.3888 million.
Hong Kong stock changes丨Junshengtai Pharmaceutical-B surged more than 44%, and the stock price hit a new high in about three weeks
Gelonghui, April 15 | Junshengtai Pharmaceutical-B (2511.HK) bucked the trend in the afternoon. At one point, it surged more than 44% to HK$6.2, recovering lost ground since April. The stock price hit a new high of about three weeks since March 26, with a market value of about HK$3.2 billion. In early April, Junshengtai Pharmaceutical announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberibe) independently developed by the company has completed patient enrollment. The trial targets patients with type 2 diabetes (T2DM) or metabolic fatty hepatosis with prediabetes. According to reports, Jun Shengtai was founded in 2011 to specialize in
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
HighTide Therapeutics (HKG:2511) has completed patient enrollment for the Phase II-b clinical trial of HTD1801, a gut-liver anti-inflammatory metabolic modulator, a Wednesday filing on the Hong Kong b
Junshengtai Pharmaceutical-B (02511.HK): HTD1801 clinical trial to treat metabolic steatohepatitis (MASH) phase IIb completed patient enrollment
Gelonghui, April 3 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberberis), developed independently by the company, has enrolled patients. The trial targets patients with metabolic fatty hepatosis (MASH for short) with type 2 diabetes (T2DM) or pre-diabetes. This trial (Centricity study) is a randomized, double-blind, placebo-controlled global multicenter phase IIb clinical trial aimed at evaluating HTD1801 in
Junshengtai Pharmaceutical-B (02511) released annual results, R&D costs of 312 million yuan, an increase of 70.6% over the previous year
Junshengtai Pharmaceutical-B (02511) announced 2023 results, other revenue and revenue of 34.2 million yuan (people...
HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING
Express News | Shenzhen Stock Exchange: Changes to the list of Hong Kong Stock Exchange securities under the Shenzhen-Hong Kong Stock Connect
Opinion | Hang Seng Index quarterly inspection results announced, which companies are expected to become the Hong Kong Stock Exchange Index?
After the market on February 16, 2024, Hang Seng Indices announced the results of its regular semi-annual index adjustments (the review ends on December 31, 2023, and is generally announced within 8 weeks after the inspection date). The scope of this adjustment covers the main flagship indices of Hong Kong stocks, such as the Hang Seng, the State-owned Enterprises Index, and the Hang Seng Technology Index; in addition, the Hang Seng Composite Index, which directly determines the scope of investment in Hong Kong Stock Connect, has also been adjusted.
The results of the Hang Seng Index quarterly inspection are about to be announced. CICC predicts that these 7 companies are expected to “dye blue”
However, CICC also pointed out that historical experience shows that the actual quarterly inspection results may be significantly different from this forecast. For example, Kuaishou and JD Logistics were both favored in past predictions, but in the end, they were not included in the Hang Seng Index.
Junshengtai Pharmaceutical-B (02511): Li Li resigns as non-executive director
Zhitong Finance App News, Junshengtai Pharmaceutical-B (02511) issued an announcement. Li Li has resigned as a non-executive director due to his intention to invest more time in his personal affairs, with effect from February 2, 2024.
HighTide Therapeutics to Set Up New Plant in China Expansion Plans
HighTide Therapeutics (HKG:2511) intends to establish a new northern China operational base and material production facility as part of plans to expand in China's Hebei Province. The biopharmaceutical
Selected Announcements | China Merchants Bank's net profit last year exceeded 146.6 billion yuan; China Telecom's 5G users increased by 50.7 million last year
Haifeng International issued a profit warning. The profit due to shareholders in 2023 is expected to be about 530 million US dollars, down about 73% from the previous year; Zero Sports Auto will issue H shares and domestic shares to raise up to 600 million yuan.
Junshengtai Pharmaceutical-B (02511.HK) plans to expand its business layout to Hebei Province
Gelonghui, January 19 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Group plans to expand its business layout to Hebei Province, China. Currently, the Group has offices and R&D centers in Shenzhen, Shanghai, Nanchang and Hong Kong. Through the expansion of its business layout in Hebei Province, the Group expects to attract top talents with strong academic backgrounds and industry experience in North China to further strengthen and enrich the Group's industry and regulatory registration resources and/or raw material supply capacity. Possible business expansion measures include the establishment of a new North China cooperative planning, registration management and/or raw material production and operation base. The above business
Rekindle the money-making effect? Inventory and outlook of Hong Kong stock IPOs
Along with expectations of valuation restoration, market sentiment is expected to gradually pick up, and new share purchases may become popular again.
Hightide Therapeutics Gains 7% in Hong Kong Trading Debut
Hightide Therapeutics (HKG:2511) gained 7.7% in its trading debut in Hong Kong on Friday, Dec. 22. The integrated biopharmaceutical company opened HK$11.92 per share, higher than its initial public of
First day of IPO | Junshengtai Pharmaceutical-B opened 3.65% higher, total market value over HK$6 billion
In Futu's dark market trading on the previous trading day, Junshengtai Pharmaceutical-B opened flat and closed down 1.68% to HK$10.52, with a turnover of HK$1,2096 million.
Junshengtai Pharmaceutical-B (02511) was publicly sold and is expected to be listed on December 22 by 32.22 times
Junshengtai Pharmaceutical-B (02511) announced the allotment results. The company sold 24.194 million shares globally, making a public offering...
Analysis
Price Target
No Data
